Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TAB006, as Monotherapy and in Combination With Toripalimab, in Patients With Previously Treated, Advanced Malignancies

NCT05253105 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT05253105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05253105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TAB006, as Monotherapy and in Combination With Toripalimab, in Patients With Previously Treated, Advanced Malignancies
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 1
Overall status
Withdrawn
Start date
March 15, 2022
Completion date
January 31, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

malignancies, previously treated, advanced